România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

egis pharmaceuticals plc - voriconazolum - pulb. pt. sol. perf. - 200mg - antimicotice de uz sistemic derivati de triazol

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

beaufour ipsen industrie - franta - troxerutinum (combinatii) - caps. - medicatia capilarelor (capilarotonice) bioflavonoide

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

elpen pharmaceutical co. inc. - grecia - voriconazolum - pulb. pt. sol. perf. - 200mg - antimicotice de uz sistemic derivati de triazol

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rompharm company s.r.l. - romania - voriconazolum - pulb. pt. conc. pt. sol. perf. - 200mg - antimicotice de uz sistemic derivati de triazol

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - metamizolum + pitofenonum hydrochloridum + fenpiverinum bromidum - soluţie injectabilă - 500 mg/2 mg/0,02 mg/ml

Uniunea Europeană - română - EMA (European Medicines Agency)

instituto grifols s.a. - imunoglobulina umană normală - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - seruri imune și imunoglobuline, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

roche pharma ag - germania - interferonum alfa 2a - sol. inj. - 9milioaneui/0,5ml - imunostimulante interferoni

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

zentiva s.a. - romania - voriconazolum - compr. film. - 200mg - antimicotice de uz sistemic derivati de triazol

Uniunea Europeană - română - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - respingerea grefei - imunosupresoare - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - suspensie orala - 40 mg/ml